Shares of Prime Medicine, Inc. (PRME) have gained 24.1% over the past four weeks to close the last trading session at $6.54, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.45 indicates a potential upside of 121%. The average comprises 11 short-term price targets ranging from a low of $9 to a high of $21, with a standard deviation of $4.34. While the lowest estimate indicate ...

Shares of Prime Medicine, Inc. (PRME) have gained 18% over the past four weeks to close the last trading session at $6.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15 indicates a potential upside of 133.6%. They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with ...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY. A live audio webcast of the fireside chat will be availabl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) (State ...

Exhibit 99.1 "In 2024, we expect to bring the first-ever Prime Editing-based product candidate to patients, while continuing to strengthen our modular Prime Editing platform and advance our next wave of programs across a range of target tissues," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "In recent months, we made meaningful progress toward this goal. In April, the U.S. Food and Drug Administration (FDA) cleared our investigational new drug (IND) application for ...

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 -- -- Appointed Tony Coles, M.D. as senior advisor -- CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company ...

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new precli ...

First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine's Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New D ...

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award -- CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class o ...

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award -- CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class o ...